Macrocyclic peptides represent a new drug class combining the oral bioavailability of small molecules with the targeting precision of biologics. Enlicitide (Lipfendra), an oral PCSK9 inhibitor approved by the FDA, lowers LDL cholesterol by 60% and was developed over 13 years using mRNA display technology, demonstrating how novel chemistry and directed evolution can overcome challenging protein targets where conventional approaches fail.